AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31896519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin/doxorubicin (Stratum A)
Number of subjects: 42
Study 31896519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin/gemcitabine (Stratum B)
Number of subjects: 42
Study 31896519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin monotherapy (Stratum C)
Number of subjects: 42
Study 31896519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (all strata)
Number of subjects: 42
Study 31896540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score
Number of subjects: 632
Study 31897475 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous fiber
Number of subjects: 3877
Study 31897676 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy
Number of subjects: 0
Study 31897939 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Scanning Test (VST)
Number of subjects: 86
Study 31898051 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoZip™ system for gastric volume reduction
Number of subjects: 11
Study 31898051 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoZip™ system
Number of subjects: 11
Study 31898110 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillectomy (EP)
Number of subjects: 62
Study 31898493 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) at a low dose of 75μg/d for 1 month, adjusted to 150μg/d if lesions did not improve, for a total treatment duration of 6 months.
Number of subjects: 24
Study 31898757 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 200
Study 31899729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholic acid (10-15 mg·kg·day)
Number of subjects: 53
Study 31899873 — intervention group
Group type: EXPERIMENTAL
Intervention: BBBD with MR-guided focused ultrasound (MRgFUS) during adjuvant TMZ chemotherapy
Number of subjects: 6
Study 31900121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg i.v. every 2 weeks for 4 cycles preoperatively with concomitant radiation therapy of bladder and pelvic region (max. 50.4 Gy)
Number of subjects: 33
Study 31900186 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular porcine corneal stroma (APCS) transplantation
Number of subjects: 39
Study 31900292 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD gut microbes transplantation (HFD-FMT)
Number of subjects: 2
Study 31900292 — intervention group
Group type: COMPARATOR
Intervention: ND gut microbes transplantation
Number of subjects: 2
Study 31900808 — intervention group
Group type: EXPERIMENTAL
Intervention: ER or PR+/Her2neu-
Number of subjects: 734
Study 31900808 — intervention group
Group type: EXPERIMENTAL
Intervention: Her2neu+
Number of subjects: 734
Study 31900808 — intervention group
Group type: COMPARATOR
Intervention: ER and PR-/Her2neu-
Number of subjects: 734
Study 31901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ReHo in the bilateral dorsal anterior cingulate cortex (dACC)
Number of subjects: 76
Study 31901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ReHo in the right middle temporal gyrus
Number of subjects: 76
Study 31901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower functional connectivity between the dACC and the precuneus
Number of subjects: 76
Study 31901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance and executive functions measured with Dementia Rating Scale, Trail-Making Test (A and B), Stroop Color Word Test, and Digit Span Test
Number of subjects: 76
Study 31901758 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 6508
Study 31902278 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SDB (57 patients)
Number of subjects: 113
Study 31902278 — intervention group
Group type: COMPARATOR
Intervention: Patients without SDB (56 patients)
Number of subjects: 113
Study 31902325 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting cognitive impairment identified using the 16-item Informant Questionnaire for Cognitive Decline in the Elderly
Number of subjects: 1102
Study 31902325 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lacunes
Number of subjects: 1102
Study 31902458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) for STSE, 30% (8/27) of responders routinely treated STSE with IMRT.
Number of subjects: 27
Study 31902458 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 27
Study 31902581 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (16-week trial)
Number of subjects: 55
Study 31902592 — intervention group
Group type: EXPERIMENTAL
Intervention: Skip metastases (pN0N2)
Number of subjects: 2653
Study 31902592 — intervention group
Group type: COMPARATOR
Intervention: N2 non-small cell lung cancer without skip metastases
Number of subjects: 2653
Study 31902946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 167
Study 31903182 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP plus B-cell receptor/NF-κB-double-targeting
Number of subjects: 0
Study 31904267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 0
Study 31905039 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-Centered Narrative Intervention
Number of subjects: 0
Study 31905039 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 31905352 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth rate measurements in patients with geographic atrophy (GA)
Number of subjects: 112
Study 31905377 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI cutoff of 2.5 ng/L
Number of subjects: 1896
Study 31905377 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT concentrations less than 5 ng/L
Number of subjects: 1896
Study 31905377 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI concentrations less than 2 ng/L
Number of subjects: 1896
Study 31905403 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight loss group
Number of subjects: 37
Study 31905403 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight retention group
Number of subjects: 37
Study 31906435 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo
Number of subjects: 0
Study 31906435 — intervention group
Group type: COMPARATOR
Intervention: Deceptive Placebo
Number of subjects: 0
Study 31906738 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative faecal immunochemical test
Number of subjects: 0
Study 31906738 — intervention group
Group type: COMPARATOR
Intervention: Symptoms suspected for colorectal cancer
Number of subjects: 0
Study 31906829 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision grip force control intervention (Strength-Dexterity test)
Number of subjects: 80
Study 31906923 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational cohort study with community health workers (Especialistas) conducting research activities and data collection.
Number of subjects: 1000
Study 31906923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study framework for diabetes research and care.
Number of subjects: 1000
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAD longitudinal cohort study (EPAD-LCS) participation
Number of subjects: 16877
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical cohort prescreening
Number of subjects: 16877
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: Research in-person cohort prescreening
Number of subjects: 16877
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: Research online cohort prescreening
Number of subjects: 16877
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based cohort prescreening
Number of subjects: 16877
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid positivity among EPAD-LCS participants
Number of subjects: 16877
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predicting participation in EPAD-LCS
Number of subjects: 16877
Study 31907067 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predicting amyloid positivity among EPAD-LCS participants
Number of subjects: 16877
Study 31907183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Chloroquine
Number of subjects: 0
Study 31907183 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Chloroquine
Number of subjects: 0
Study 31907538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 29
Study 31907538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c
Number of subjects: 29
Study 31907538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower adrenocorticotropin
Number of subjects: 29
Study 31907538 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD correlation with parathyroid hormone, FGF23, thyrotropin, and glycated hemoglobin (HbA1c) levels
Number of subjects: 29
Study 31907538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture history
Number of subjects: 29
Study 31907538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean final heights
Number of subjects: 29
Study 31907538 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal BMD
Number of subjects: 29
Study 31907737 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome and transcriptome analysis (WGTA)
Number of subjects: 28
Study 31907737 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched treatment based on molecular targets
Number of subjects: 28
Study 31907737 — intervention group
Group type: COMPARATOR
Intervention: Single-gene DNA changes
Number of subjects: 28
Study 31907737 — intervention group
Group type: COMPARATOR
Intervention: Genome-wide data or RNA gene expression
Number of subjects: 28
Study 31907737 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration
Number of subjects: 28
Study 31907828 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose 50 mg for 1 week
Number of subjects: 11
Study 31907828 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg for 1 week
Number of subjects: 11
Study 31907828 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 120 mg for 1 week
Number of subjects: 11
Study 31907828 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg for 3 weeks
Number of subjects: 11
Study 31907828 — intervention group
Group type: EXPERIMENTAL
Intervention: pasireotide 300 μg as a single dose
Number of subjects: 11
Study 31907828 — intervention group
Group type: COMPARATOR
Intervention: baseline liquid mixed meal test (MMT)
Number of subjects: 11
Study 31908107 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent alcohol-dependent patients
Number of subjects: 96
Study 31908107 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective craving
Number of subjects: 96
Study 31908107 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsivity of alcohol use
Number of subjects: 96
Study 31908426 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable pen
Number of subjects: 116
Study 31908441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator Responsiveness (BDR)
Number of subjects: 2974
Study 31908444 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD D patients
Number of subjects: 3253
Study 31908444 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily variability in chest tightness and wheezing
Number of subjects: 3253
Study 31908462 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PANSS positive dimension ratings
Number of subjects: 1379
Study 31908462 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PANSS negative dimension ratings
Number of subjects: 1379
Study 31908462 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS depression ratings
Number of subjects: 1379
Study 31908462 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe cognitive/disorganized PANSS symptoms
Number of subjects: 1379
Study 31908520 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine combined with 2 μg/kg dexmedetomidine (LD group)
Number of subjects: 90
Study 31908520 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine (H group)
Number of subjects: 90
Study 31908520 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine (L group)
Number of subjects: 90
Study 31908779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 201
Study 31908779 — intervention group
Group type: COMPARATOR
Intervention: Non-dexmedetomidine (non-DEX)
Number of subjects: 201
Study 31908788 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 332
Study 31908788 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime SpO2
Number of subjects: 332
Study 31908791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment
Number of subjects: 5
Study 31908791 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5
Study 31908813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (combined dose group)
Number of subjects: 234
Study 31909303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil and subcutaneous BNP
Number of subjects: 21
Study 31909303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21
Study 31910037 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Sepsis-related Organ Failure Assessment Score
Number of subjects: 0
Study 31910037 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31910750 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention for Hoarding Disorder (CTI-HD)
Number of subjects: 14
Study 31910859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 12806
Study 31910885 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaries completed continuously or intermittently
Number of subjects: 0
Study 31910885 — intervention group
Group type: COMPARATOR
Intervention: Investigator-led interviews
Number of subjects: 0
Study 31910885 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaries (general)
Number of subjects: 0
Study 31910885 — intervention group
Group type: COMPARATOR
Intervention: Case report forms (CRFs) completed by investigators
Number of subjects: 0
Study 31910916 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 35
Study 31910916 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy for Cognitively Impaired Older Adults (ST-CI)
Number of subjects: 35
Study 31911180 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib + Sodium Valproate
Number of subjects: 0
Study 31911180 — intervention group
Group type: EXPERIMENTAL
Intervention: Knock down of ERBB3
Number of subjects: 0
Study 31911180 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib
Number of subjects: 0
Study 31911527 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative covert stroke
Number of subjects: 0
Study 31911527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function evaluation
Number of subjects: 0
Study 31911527 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 0
Study 31911527 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum immune-inflammatory cytokines
Number of subjects: 0
Study 31911839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (MabThera)
Number of subjects: 0
Study 31912137 — intervention group
Group type: EXPERIMENTAL
Intervention: CNC patients with systematic follow-up and screening for manifestations
Number of subjects: 70
Study 31912137 — intervention group
Group type: EXPERIMENTAL
Intervention: CNC patients with systematic follow-up
Number of subjects: 70
Study 31912137 — intervention group
Group type: EXPERIMENTAL
Intervention: CNC patients with PRKAR1A c.709-7del6 mutation
Number of subjects: 70
Study 31912154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome patients in remission
Number of subjects: 36
Study 31912203 — intervention group
Group type: EXPERIMENTAL
Intervention: 2004 study
Number of subjects: 26024
Study 31912203 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010 study
Number of subjects: 26024
Study 31912203 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 study
Number of subjects: 26024
Study 31912203 — intervention group
Group type: COMPARATOR
Intervention: 1998 study
Number of subjects: 26024
Study 31912438 — intervention group
Group type: EXPERIMENTAL
Intervention: CCUS performed by medical students
Number of subjects: 1212
Study 31912438 — intervention group
Group type: COMPARATOR
Intervention: CO measurements by experts
Number of subjects: 1212
Study 31912438 — intervention group
Group type: EXPERIMENTAL
Intervention: CCUS measurements by both medical students and experts
Number of subjects: 1212
Study 31912454 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 0
Study 31912454 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study 31912454 — intervention group
Group type: COMPARATOR
Intervention: Cannabidiol
Number of subjects: 0
Study 31912462 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg once daily
Number of subjects: 0
Study 31912462 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily
Number of subjects: 0
Study 31912462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 31912493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (mean daily dose 7.0 mg/day)
Number of subjects: 180
Study 31912493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 180
Study 31912874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 19
Study 31912905 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 0
Study 31912905 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib plus HDAC inhibitors
Number of subjects: 0
Study 31912961 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation (Tx)
Number of subjects: 88
Study 31912961 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 31912991 — intervention group
Group type: EXPERIMENTAL
Intervention: cQFR
Number of subjects: 130
Study 31912991 — intervention group
Group type: EXPERIMENTAL
Intervention: HFV
Number of subjects: 130
Study 31912991 — intervention group
Group type: EXPERIMENTAL
Intervention: cQFR-fQFR
Number of subjects: 130
Study 31913135 — intervention group
Group type: EXPERIMENTAL
Intervention: Study duration of 5 days
Number of subjects: 640
Study 31913135 — intervention group
Group type: EXPERIMENTAL
Intervention: Study duration of 15 days
Number of subjects: 640
Study 31913135 — intervention group
Group type: EXPERIMENTAL
Intervention: Study duration of 27 days
Number of subjects: 640
Study 31913135 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification level light
Number of subjects: 640
Study 31913135 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification level moderate
Number of subjects: 640
Study 31913135 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study completion rates
Number of subjects: 640
Study 31913135 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically meaningful results from trials
Number of subjects: 640
Study 31913732 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion (CL) re-MI
Number of subjects: 108615
Study 31913732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesion (NCL) re-MI
Number of subjects: 108615
Study 31913732 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate re-MIs
Number of subjects: 108615
Study 31913732 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel disease
Number of subjects: 108615
Study 31913732 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 108615
Study 31913732 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged time between index and re-MI
Number of subjects: 108615
Study 31914032 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal anastomosis testing (testing for blood supply by ICG fluorescence, mechanical integrity by air-leak and methylene blue leak tests, and tension testing)
Number of subjects: 0
Study 31914032 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal anastomosis testing
Number of subjects: 0
Study 31914936 — intervention group
Group type: EXPERIMENTAL
Intervention: iSupport online program for three months
Number of subjects: 184
Study 31914936 — intervention group
Group type: COMPARATOR
Intervention: Education-only e-book (comparison group)
Number of subjects: 184
Study 31914997 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (home-based outreach by Community Health Representatives)
Number of subjects: 7
Study 31914997 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (health education delivered by CHRs)
Number of subjects: 7
Study 31914997 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (education for family members by CHRs)
Number of subjects: 7
Study 31914997 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (support for patients unable to see a primary care doctor)
Number of subjects: 7
Study 31914997 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (trusting client-CHR relationships)
Number of subjects: 7
Study 31915000 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP+ programme (a multicomponent programme delivered stepwise over an eight-month period with the help of an external trainer)
Number of subjects: 14
Study 31915000 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP+ programme
Number of subjects: 14
Study 31915000 — intervention group
Group type: COMPARATOR
Intervention: Care and education as usual
Number of subjects: 14
Study 31915028 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPK2 gene variant (rs2030712)
Number of subjects: 169
Study 31915030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography using a stabilizing device
Number of subjects: 51
Study 31915030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ECUS and transit-time flow measurement (TTFM)
Number of subjects: 51